Kornimate/medical-research-clean huggingface dataset:
yoga impact in fibromyalgia, primary health care

Conditions: Fibromyalgia

Summary: this study aims to evaluate the effectiveness of a complementary therapy using yoga within the scope of first health care in portugal, in pain control, quality of life and well-being of the patients with fibromyalgia. it also, pretends to assess the viability and to identify the barriers to this sort of therapy in the context of primary health care.

fibromyalgia is a chronic and debilitating pain syndrome characterized by widespread and persistent pain, also affecting sleep quality and cognitive function. it is estimated to affect 3.6% of the population; however, since it is a condition that is often underdiagnosed, the actual numbers may be higher. it is also an incurable disease, so treatment is based on symptom management through pharmacological therapy, which is not always effective. due to the inadequacy of pharmacological therapy, there is a need for complementary therapies, and despite the limited number of studies conducted in this area, some therapies based on meditative movement (notably yoga) are beginning to emerge, with beneficial effects reported on pain management and quality of life in these patients. therefore, this study aims to investigate the benefits and feasibility of this type of intervention at the primary health care level.

Eligibility criteria:
inclusion criteria: * users of the family health unit diagnosed with fibromyalgia; * with cognitive capacity to answer the questionnaire; * with physical capacity to take part in yoga classes. exclusion criteria: * people under 18 years old.

Keywords: fibromyalgia chronic pain yoga complementary and alternative medicine
a multicenter vesicare® efficacy and safety study for the treatment of urgency associated with overactive bladder (oab)

Conditions: Urinary Bladder, Overactive

Summary: the purpose is to evaluate the efficacy of 5 and 10mg vesicare® (solifenacin succinate) in patients with urgency who have overactive bladder syndrome.


Eligibility criteria:
inclusion criteria: * at least 1 urinary urgency episode/24h (on average) documented in a 3-day patient diary in the screening phase with or without urge incontinence, and usually with frequency and nocturia, described as oab * patients may be included if they were never exposed to anticholinergic agents specified for the treatment of oab. patients may also be included if they have previously been treated with fda-approved anticholinergic agents for the treatment of oab such as oxybutynin chloride and are no longer receiving such treatment for a minimum of 14 days immediately preceding entry into the study. these previously treated patients must present at the investigative site on no anticholinergic agents and with the desire to receive treatment for oab. previous non-drug treatment of oab is allowed if it has been established at least 4 weeks prior to study entry and is continued throughout the study. * patients having urgency with or without urge incontinence accompanied by frequency of ≥8 episodes per 24 hours, and/or nocturia, for a period of ≥3 months prior to screening. exclusion criteria: * previous treatment with darifenacin * duration of urgency with or without urge incontinence, usually accompanied with frequency and nocturia for \<3 months * significant stress incontinence or mixed stress/urge incontinence where stress is the predominant factor as determined by the investigator * evidence of a urinary tract infection; chronic inflammation such as interstitial cystitis and bladder stones * clinically significant outflow obstruction (benign prostatic hyperplasia) as determined by the investigator

Keywords: urinary bladder, overactive urgency vesicare® solifenacin succinate
cure addiction center of excellence: brain mechanisms of relapse and recovery

Conditions: Prescription Opiate/Medication Dependence

Summary: the proposed project will use fmri and specific probes of reward and inhibition as biomarkers predicting drug use during and after treatment in 72 subjects addicted to prescription opioids/medications. subjects will be scanned before, during, and after 12 weeks of active medication. the brain fmri measures will be correlated with the primary clinical outcome of drug use (by urine drug screen) during the treatment and follow-up phase.


Eligibility criteria:
inclusion criteria: 1. sign an informed consent form; 2. be between the ages of 18 and 60; 3. have a diagnosis of opioid dependence according to dsm iv-tr criteria (as assessed by the mini); 4. be in good general health as determined by complete physical examination and laboratory tests; 5. have a negative result for urinary opioids and must self report being at least 3 days opioid free. participants may have a diagnosis of alcohol dependence so long as they do not have severe alcohol dependence that requires medical supervision for alcohol withdrawal. exclusion criteria: 1. current severe alcohol dependence that requires medical supervision for alcohol withdrawal; 2. current psychosis, dementia, mental retardation, or history of schizophrenia; 3. significant clinical abnormalities in hematology, chemistry, or urinalysis; 4. significant clinical cardiovascular, neurological, hepatic, renal, pulmonary, metabolic, endocrine, or gastrointestinal disorders; 5. female subjects who are pregnant or lactating, or female subjects of childbearing potential who are not using birth control (oral contraceptives, barrier (diaphragm or condom) plus spermicide, or levonorgestrel implant); (pregnancy testing will be done on all females of child bearing age); and 6. current diagnosis of chronic pain disorder.

Keywords: prescription opiates/medications vivitrol brain imaging
evaluation of pediatric procedural sedation with rectal chloral hydrate or intranasal midazolam

Conditions: Traumatic Brain Injury; Computed Tomography; Procedural Sedation

Summary: thousands of children receive sedation for diagnostic and therapeutic interventions annually, and this number is expected to increase. children are at higher risk for sedation-related complications than adults. in different scenarios, multiple drugs are used to achieve sedation, each one with particular adverse events that must be monitored and reported. children that need ct scans for traumatic brain injuries often need sedation, without needing and iv line for that. chloral hydrate is an hypnotic agent used since 1832 with low incidence of adverse events; however, despite its worldwide use, it's being abandoned due to bitter taste, long time of sedation onset, vomiting and mild sedation. intranasal midazolam, on the other hand, produces high and fast concentrations on csf with greater rates of success but probably with higher adverse events. there are no prospective studies with large series of patients using intranasal midazolam. the aim of this study is to determine if nasal midazolam is a safer approach and more effective sedative regimen when compared to rectal chloral hydrate to children undergoing ct scans.


Eligibility criteria:
inclusion criteria: * children undergoing ct scanning for tbi exclusion criteria: * epistaxis * suspected or confirmed skull or nasal fracture * moderate to severe traumatic brain injury * hemodynamically unstable

Keywords: deep sedation pediatrics emergency hospital services midazolam chloral hydrate randomized controlled trial
efficacy and tolerance study on the use of the in-exsufflator in the hospitalized elderly

Conditions: Airway Obstruction

Summary: the mechanical in-exsufflator (mi-e) is a medical device used to facilitate coughing when the patients' cough is not efficient. studies have shown positive results in helping airway clearance in children and adults with neuromuscular disorders however there is lack of evidence in older populations. this study's aim is to evaluate the feasibility of the mi-e in older adults. the hypothesis is that the use of mi-e in older adults is feasible.

background: one of the most frequent reasons for hospital admission of older adults are respiratory disorders. physiological aging processes decrease respiratory muscle strength and can reduce the efficacity of cough. the mechanical in-exsufflator (mi-e) is a medical device used to help coughing. studies have shown positive results in helping airway clearance in children and adults with neuromuscular pathologies however there is lack of evidence in older populations. this study's aim is to evaluate the feasibility of the mi-e in older adults. the hypothesis is that the use of mi-e in older adults is feasible. methods: feasibility will be evaluated by outcomes such as the discomfort of each session (use of a numerical scale of discomfort from 0 to 10) and the relief felt before and after each session (use of a modified borg scale to quantify dyspnea). two sessions a day of mi-e will be done for a total of four sessions. furthermore, other outcomes shall be used, before and after each session, such as vital signs (heart and respiratory rate, blood pressure and oxygen saturation), auscultation as well as the measure of cough peak flow. discussion: the protocol of this study is the first to evaluate the use of mi-e in hospitalized older adults by the measure of discomfort and relief. in regard to literature on the use of mi-e in patients suffering from neuromuscular pathologies and on the effects of aging on the respiratory system, the hypothesis of the study seems justified. on top of bringing physical benefits to the patient, the study will pave the way for other randomized controlled studies.

Eligibility criteria:
inclusion criteria: * patient hospitalize in intensive care unit or pulmonary unit, * having airway clearance problem associated with mucus hypersecretion, * peak expiratory flow (pef) \<280 l/min, * medical indication for respiratory physical therapy. exclusion criteria: * contraindication to use of mi-e device (ex. bronchospasm, immediate follow-up to surgery of airway system, chest or abdominal region, untreated pneumothorax, hemodynamic failure, etc.), * refuse to participate, * pregnant, * breastfeeding, * insufficient cognitive status.

Keywords: airway obstruction mechanical insufflator exsufflator older adults
can a brief primary care intervention affect healthy weight habits

Conditions: Obesity

Summary: parents should receive anticipatory guidance about obesity prevention as part of the routine well child visit. educational resources are needed to help physicians routinely provide these important anticipatory guidance messages. in this study, consecutive parents will be exposed to routine anticipatory guidance messages before the well child visit with the physician. after the clinic visit, parents will be invited to participate in a research study to determine if they plan any changes at home. the key research question of this study is: can a brief multimedia intervention help parents develop plans to help their children have a healthy weight?


Eligibility criteria:
inclusion criteria: * english and spanish speaking parents of 2-12 year old children presenting to the pediatric primary care clinic. exclusion criteria: * parent does not speak english or spanish. * child presenting for an acute care visit.

Keywords: obesity prevention primary care education
glycemic control and diabetic macular edema

Conditions: Diabetic Macular Edema

Summary: does diabetic patients' glycemic control affect their response to laser and/or intravitreal injection therapy in terms of visual and anatomical outcomes.

to evaluate the visual and anatomical response to therapy in patients with diabetic macular edema (dme) in relation to their glycemic control. patients with dme with central foveal thickness (cft) \> 250µm with no proliferative disease had their glycosolated hemoglobin (hba1c) measured at baseline and 3 months. cft by optical coherence tomography, and best corrected visual acuity (bcva) in logmars were measured at baseline, 1, and 3 months. exclusion criteria: laser or intravitreal injections within 6 months, hard exudates within 500um of the foveal center, or macular traction. therapy included laser and intravitreal anti vegfs. hba1c graded as: g1=\ 9%; and as: low \<8%, high ≥ 8%.

Eligibility criteria:
inclusion criteria: * central foveal thickness more than 250 microns exclusion criteria: * proliferative diabetic retinopathy. * traction macular membranes * previous laser or intravitreal injections within 6 months.

Keywords: diabetic macular edema, glycemic control
effects of combined natural molecules on metabolic syndrome in menopausal women

Conditions: Menopause; Climacteric Syndrome; Metabolic Syndrome

Summary: the study collected retrospective data from the assumption of combined natural molecules in menopausal women with metabolic syndrome


Eligibility criteria:
inclusion criteria: * menopause * diagnosis of metabolic syndrome exclusion criteria: * pharmacologically-induced menopause * hormonal therapies * sensitizing insulin therapies * cancer patient or ex-cancer patient
analysis of expression of specific markers and their prognostic significance in hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: hepatocellular carcinoma is an aggressive disease with limited therapeutic options. therefore, new approaches to treat this type of cancer are needed with immunotherapy potentially being one of these. as a first step in the development of novel therapies, expression analysis of specific markers, including tumor antigens will be carried out, and the correlation of expression with disease variables and clinical outcome will be assessed. this will be done retrospectively using archived hepatocellular carcinoma tissue samples.


Eligibility criteria:
inclusion criteria: * the patient has pathologically proven hepatocellular carcinoma (any stage) * all the data required are available from patient's records exclusion criteria: n/a

Keywords: prognosis markers expression analysis hepatocellular carcinoma
telemedicine in hiv care in buenos aires

Conditions: Telemedicine; HIV-1-infection

Summary: the aim of this investigation is to conduct an implementation research to facilitate and evaluate the implementation of vct((videoconsult through telemedicine) among hiv hcp(healthcare providers) and plwh(people living with hiv)

through prospective observational methodology the investigators are planning to evaluate vct(videoconsult through telemedicine) implementation. both quantitative and qualitative analysis (mixed methods) will take part in the assessment. quantitative data will be useful to obtain objective data in terms of proportion of subjects using the intervention, adoption by health care workers and measuring effectiveness. additionally, qualitative methods will help to understand the outcomes focusing on the barriers and facilitators from both the hcw and patients, and their feedback on continuous implementation. hence, perceptions of a vast group of patients and hcw will take a critical point in the qualitative analysis. finally, by evidencing effectiveness, the investigators will be able to generalize and maintain this intervention as a good clinical practice. due to the scope of the outcomes, the investigators will use re-aim framework.

Eligibility criteria:
inclusion criteria: * 18 years-old or older * access to internet * willing to participate exclusion criteria: * do not understand the purpose and study procedures
adjuvant intravitreal bevacizumab in pars plana vitrectomy for vitreous hemorrhage

Conditions: Vitreous Hemorrhage Secondary to PDR

Summary: the purpose of this study is to determine the effect of pre and intra-operative bevacizumab injection on postoperative vitreous hemorrhage after diabetic vitrectomy in comparison to vitrectomy without bevacizumab injection.

postoperative vitreous hemorrhage is a common complication after vitrectomy for proliferative diabetic retinopathy. bevacizumab (avastin) is a potent inhibitor of angiogenesis and has been shown to decrease retinal and iris neovascularization in proliferative diabetic retinopathy. we believe that preoperative bevacizumab injection could reduce postoperative vitreous hemorrhage by decreasing the amount of abnormal vessels and intraoperative injection could also reduce postoperative vitreous hemorrhage by inhibiting the vessel formation after surgery

Eligibility criteria:
inclusion criteria: * patients undergoing first vitrectomy for vitreous hemorrhage secondary to proliferative diabetic retinopathy exclusion criteria: * follow-up period of less than 3 months * not first vitrectomy * abnormal blood coagulation * uncontrolled hypertension

Keywords: bevacizumab vitreous hemorrhage diabetes mellitus
the effect of low oxygen tension on the early development of human embryo in ivf/icsi

Conditions: Embryo Hypoxia

Summary: to investigate the effect of low oxygen tension during in vitro culture in terms of embryo quality and outcomes of pregnancy in vitro fertilization/ intracytoplasmic sperm injection

the oocytes will be divided into two parts(two groups) form one patient. the two groups of oocytes will be cultured seperately in the incubator with the concentrations of 5% co2,6%o2,89% n2(low oxygen concentration) verse 6% co2,20% o2,74% n2(in atmosphere). a series of observational measurement(embryo quality and outcomes of pregnancy) will be performed.

Eligibility criteria:
inclusion criteria: * fresh cycles of in vitro fertilization/intracytoplasmic sperm injection and emrbyo transfer (ivf/icsi-et) * ≥ 10 oocytes after oocyte retrieval exclusion criteria: * ≥ 3 transfer or oocyte retrieval cycles * pgd/pgs cycles * half-icsi/rescure icsi * fluid in the uterine cavity, abnormal endometrium, uterine abnormalities,pelvic inflammation * acute maternal problems. * one or both spouses have an abnormal karyotype (including polymorphism)

Keywords: low oxygen tension embryo quality
99mtc/68ga labeled anti-pd-l1 sdab in assessment of pd-l1 expression in nsclc

Conditions: Non-Small Cell Lung Cancer

Summary: to evaluate the safety, dosimetry and efficacy of 99mtc/68ga labeled anti-pd-l1 single domian antibody (sdab) (product code name: 99mtc-nm-01 and 68ga-nm-01) in the diagnostic imaging pd-l1 expression in non-small cell lung cancer (nsclc) and compare it with the existing gold standard "biopsy pd-l1 detection". it is also to establish a new clinical method of non-invasive pd-l1 expression detection in nsclc using 99mtc/68ga labeled anti-pd-l1 sdab.


Eligibility criteria:
inclusion criteria: * participant is willing and able to give informed consent for the participation in the study before any protocol-specific screening procedures are performed * male or female, aged 18-75 years old * previous diagnosis of non-small cell carcinoma, confirmed with pathology tests * ast, alt, bun, cr not more than double the normal values * patients with no current history of hepatitis a, hepatitis b, aids, tuberculosis and other infectious diseases exclusion criteria: * severe infection * unable to provide biopsy sample for testing pd-l1 expression level * patients with pacemakers * pregnant and lactating women * investigators professional decision that the subject should not participate in this clinical study
by using adoptive transfer of autologous nk cells to prevent recurrence of hepatocellular carcinoma after curative therapy

Conditions: Hepatocellular Carcinoma

Summary: to prove that the efficacy and safety of 'nk group' is superior to 'non-treatment group(control group)' in patient undergone curative resection(rfa or operation) for hepatocellular carcinoma in china.

no adjuvant therapy has been shown to extend the survival of patients with hepatocellular carcinoma receiving curative treatment.we investigated whether injections of nk cells prolongs recurrence-free survival of patients after curative therapy.

Eligibility criteria:
inclusion criteria: 1. prior to the test, patient is fully explained about the purpose/ contents and characteristics of the testing medication, and the patient him(her)self, the guardian or the legal representative signed on written consent. 2. gender unlimited, age from 18 years to 70 years 3. the patient is diagnosed as hepatocellular carcinoma by pathological/ radiological test and he (she) is in the stage of i or ii. (refer to the attached file 10). hepatocellular carcinoma should be shown by radiological test; on dynamic ct, dynamic mri or on angiography. 4. child-pugh score should be less than 6 5. no matter how the patient has been treated before, his (her) tumor should be totally removed by curative resection (rfa or operation). (based on the agreement date for written consent) 6. patients must have adequate cardiac function(no cardiac disease, lvef≥40% ), adequate pulmonary function as indicated by room air oxygen saturation of \>94%, and adequate renal function(cr≤133umol/l). 7. patient's remaining life-time should be expected at least more than 3 months. exclusion criteria: 1. hepatocellular carcinoma has been transferred by pathological/ radiological test (stage iii or stage iv, refer to the exhibit 10) 2. the carcinoma has been invaded to main portal vein or major branch hepatic vein 3. child-pugh score is over 6 4. patient has serious problem with pulmonary function by sub- investigator's opinion 5. patient who has disease history of immune deficiency 6. diagnosed as an immune deficiency patient 7. patient who has disease history of malignant tumor within 5 years before this clinical trial. 8. patient who had anti-cancer medication before the clinical trial 9. patient has serious allergic-history by sub- investigator's opinion 10. patient has serious mental disease by sub- investigator's opinion 11. pregnant women, nursing mother or having intention of being pregnant during the clinical test 12. patient who participated in other clinical trial within 4 weeks before this clinical trial 13. patient who is incongruent to this clinical trial by sub- investigator's opinion.

Keywords: hepatocellular carcinoma natural killer cells
the effects of low-level laser therapy in extensor tendon injuries between zones 5-8

Conditions: Tendon Injury - Hand

Summary: this study examines the rehabilitation results when low-level laser therapy is applied in zone 5-8 extensor tendon injuries. rehabilitation results will be evaluated with both objective measurements and patient reported outcome measures. the study was planned as a double-blind, placebo-controlled, randomized, two-arm study. participants in both treatment groups will be given exercise therapy in accordance with the early active mobilization protocol and appropriate splint will be given to be used while exercising.


Eligibility criteria:
inclusion criteria: * being between the ages of 18-65 * primary repair due to extensor tendon injury between zones v-viii * applying to the hand rehabilitation policlinic at the end of the postoperative 1st week exclusion criteria: * accompanying flexor tendon injury, fracture, vascular and / or nerve injury * active using of steroids or non-steroidal anti-inflammatory drugs * systemic infection or malignancy * pregnant or breastfeeding women * active wound infection * having a cognitive dysfunction